Media headlines about INC Research Holdings (NASDAQ:INCR) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. INC Research Holdings earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.7836848210215 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- Jefferies Upgrades INC Research Holdings (INCR) to Buy – StreetInsider.com (streetinsider.com)
- The INC Research Pullback Creates A Compelling Entry Point (finance.yahoo.com)
- INC Research Holdings (INCR) vs. Idera Pharmaceuticals (IDRA) Head to Head Comparison (americanbankingnews.com)
- INC Research Holdings, Inc. (INCR) Expected to Post Quarterly Sales of $586.58 Million (americanbankingnews.com)
Several research analysts recently issued reports on INCR shares. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $65.00 target price on shares of INC Research Holdings in a research report on Monday, August 7th. Jefferies Group LLC raised INC Research Holdings from a “hold” rating to a “buy” rating and lifted their target price for the company from $62.50 to $69.00 in a research report on Monday. Zacks Investment Research cut INC Research Holdings from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Robert W. Baird reaffirmed a “buy” rating and set a $67.00 target price on shares of INC Research Holdings in a research report on Monday. Finally, Mizuho started coverage on INC Research Holdings in a research report on Thursday, September 21st. They set a “neutral” rating and a $57.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $63.75.
Shares of INC Research Holdings (NASDAQ INCR) opened at 55.85 on Tuesday. The firm has a 50 day moving average price of $54.93 and a 200 day moving average price of $53.46. INC Research Holdings has a 52 week low of $40.65 and a 52 week high of $61.10. The company has a market capitalization of $3.03 billion, a price-to-earnings ratio of 34.22 and a beta of 1.35.
INC Research Holdings (NASDAQ:INCR) last released its earnings results on Thursday, July 27th. The company reported $0.64 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.64. The company had revenue of $258.10 million for the quarter, compared to the consensus estimate of $256.76 million. INC Research Holdings had a return on equity of 40.69% and a net margin of 5.69%. INC Research Holdings’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.61 earnings per share. Equities analysts forecast that INC Research Holdings will post $2.62 EPS for the current year.
In other INC Research Holdings news, CFO Gregory S. Rush sold 88,739 shares of the firm’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $58.99, for a total transaction of $5,234,713.61. Following the sale, the chief financial officer now directly owns 149,301 shares of the company’s stock, valued at $8,807,265.99. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Christopher L. Gaenzle sold 42,601 shares of the firm’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $58.67, for a total value of $2,499,400.67. Following the sale, the chief accounting officer now directly owns 69,557 shares in the company, valued at $4,080,909.19. The disclosure for this sale can be found here. Insiders have sold 198,321 shares of company stock worth $11,550,792 over the last quarter. 0.24% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: “INC Research Holdings (INCR) Earning Somewhat Positive Media Coverage, Study Finds” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://ledgergazette.com/2017/10/10/inc-research-holdings-incr-earning-somewhat-positive-media-coverage-study-finds.html.
INC Research Holdings Company Profile
INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.
Receive News & Ratings for INC Research Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.